MTOR and Erythema: By six months into the treatment regimen, both the size and erythema of the facial angiofibromas had visibly diminished, indicating a noteworthy and somewhat unexpected therapeutic response of these lesions to systemic mTOR inhibition with everolimus (Figure 1E).